<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN"
                           "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer Berlin Heidelberg</PublisherName>
    <PublisherLocation>Berlin/Heidelberg</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Journal OutputMedium="All">
    <JournalInfo JournalProductType="NonStandardArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>66</JournalID>
      <JournalDOI>10.1007/66.1439-099X</JournalDOI>
      <JournalPrintISSN>0179-7158</JournalPrintISSN>
      <JournalElectronicISSN>1439-099X</JournalElectronicISSN>
      <JournalTitle>Strahlentherapie und Onkologie</JournalTitle>
      <JournalSubTitle>Journal of Radiation Oncology, Biology, Physics</JournalSubTitle>
      <JournalAbbreviatedTitle>Strahlenther Onkol</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</JournalSubject>
        <JournalSubject Code="SCH29056" Priority="1" Type="Secondary">Radiotherapy</JournalSubject>
        <JournalSubject Code="SCH43008" Priority="2" Type="Secondary">Oncology</JournalSubject>
        <SubjectCollection Code="SC11">Medicine</SubjectCollection>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume OutputMedium="All">
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>191</VolumeIDStart>
        <VolumeIDEnd>191</VolumeIDEnd>
        <VolumeIssueCount>12</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular" OutputMedium="All">
        <IssueInfo IssueType="Regular" TocLevels="0">
          <IssueIDStart>6</IssueIDStart>
          <IssueIDEnd>6</IssueIDEnd>
          <IssueArticleCount>12</IssueArticleCount>
          <IssueHistory>
            <OnlineDate>
              <Year>2015</Year>
              <Month>5</Month>
              <Day>30</Day>
            </OnlineDate>
            <PrintDate>
              <Year>2015</Year>
              <Month>5</Month>
              <Day>29</Day>
            </PrintDate>
            <CoverDate>
              <Year>2015</Year>
              <Month>6</Month>
            </CoverDate>
            <PricelistYear>2015</PricelistYear>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>Springer-Verlag Berlin Heidelberg</CopyrightHolderName>
            <CopyrightYear>2015</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="s00066-014-0803-1" OutputMedium="All">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>803</ArticleID>
            <ArticleDOI>10.1007/s00066-014-0803-1</ArticleDOI>
            <ArticleSequenceNumber>4</ArticleSequenceNumber>
            <ArticleTitle Language="En">Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer</ArticleTitle>
            <ArticleSubTitle Language="En">Comparative analysis of inflammation-based prognostic scoring systems</ArticleSubTitle>
            <ArticleTitle Language="De">Primäre oder postoperative Radiotherapie bei Patienten mit Kopf-Hals-Tumoren</ArticleTitle>
            <ArticleSubTitle Language="De">Vergleichende Analyse entzündungsbasierter Bewertungssysteme</ArticleSubTitle>
            <ArticleCategory>Original Article</ArticleCategory>
            <ArticleFirstPage>486</ArticleFirstPage>
            <ArticleLastPage>494</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2014</Year>
                <Month>12</Month>
                <Day>18</Day>
              </RegistrationDate>
              <Received>
                <Year>2014</Year>
                <Month>9</Month>
                <Day>29</Day>
              </Received>
              <Accepted>
                <Year>2014</Year>
                <Month>12</Month>
                <Day>18</Day>
              </Accepted>
              <OnlineDate>
                <Year>2015</Year>
                <Month>1</Month>
                <Day>13</Day>
              </OnlineDate>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>Springer-Verlag Berlin Heidelberg</CopyrightHolderName>
              <CopyrightYear>2015</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Edgar</GivenName>
                  <FamilyName>Selzer</FamilyName>
                  <Degrees>MD</Degrees>
                </AuthorName>
                <Contact>
                  <Phone>+43 1 40400 76710</Phone>
                  <Email>edgar.selzer@meduniwien.ac.at</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Anja</GivenName>
                  <FamilyName>Grah</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Gregor</GivenName>
                  <FamilyName>Heiduschka</FamilyName>
                  <Degrees>MD</Degrees>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Gabriela</GivenName>
                  <FamilyName>Kornek</FamilyName>
                  <Degrees>MD</Degrees>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Dietmar</GivenName>
                  <FamilyName>Thurnher</FamilyName>
                  <Degrees>MD</Degrees>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Department of Radiotherapy</OrgDivision>
                <OrgName>Medical University of Vienna</OrgName>
                <OrgAddress>
                  <Street>Waehringer Guertel 18–20</Street>
                  <Postcode>1090</Postcode>
                  <City>Vienna</City>
                  <Country>Austria</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>Otorhinolaryngology—Head and Neck Surgery</OrgDivision>
                <OrgName>Medical University of Vienna</OrgName>
                <OrgAddress>
                  <City>Vienna</City>
                  <Country>Austria</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgDivision>Medicine I—Division of Clinical Oncology</OrgDivision>
                <OrgName>Medical University of Vienna</OrgName>
                <OrgAddress>
                  <City>Vienna</City>
                  <Country>Austria</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En" OutputMedium="All">
              <Heading>Abstract</Heading>
              <AbstractSection ID="ASec1">
                <Heading>Introduction</Heading>
                <Para>Inflammation-based scoring systems have potential value in evaluating the prognosis of cancer patients; however, detailed comparative analyses in well-characterized head and neck cancer patient collectives are missing.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec2">
                <Heading>Methods</Heading>
                <Para>We analyzed overall survival (OS) in locally advanced head and neck cancer patients who were treated with curative intent by primary radiotherapy (RT) alone, by RT in combination with cetuximab (RIT) or with cisplatin (RCHT), and by primary surgery followed by postoperative radiotherapy (PORT). The primary RT collective (<Emphasis Type="Italic">N</Emphasis> = 170) was analyzed separately from the surgery plus RT group (<Emphasis Type="Italic">N</Emphasis> = 148). OS was estimated using the Kaplan–Meyer method. Cox proportional-hazard regression models were applied to compare the risk of death among patients stratified according to risk factors and the inflammation-based Glasgow Prognostic Score (GPS), the modified GPS (mGPS), the neutrophil–lymphocyte ratio (NLR), the platelet–lymphocyte ratio (PLR), and the prognostic index (PI).</Para>
              </AbstractSection>
              <AbstractSection ID="ASec3">
                <Heading>Results</Heading>
                <Para>A prognostic relevance of the scoring systems for OS was observed in the primarily irradiated, but not in the PORT collective. OS was 35.5, 18.8, and 15.4 months, respectively, according to GPS 0, 1, and 2. OS according to mGPS 0–2 was identical. The PLR scoring system was not of prognostic relevance, while OS was 27.3 months in the NLR 0 group and 17.3 months in the NLR 1 group. OS was 35.5 months in PI 0, 16.1 months in PI 1, and 22.6 months in PI 2.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec4">
                <Heading>Conclusion</Heading>
                <Para>GPS/mGPS scoring systems are able to discriminate between three risk groups in primarily, but not postoperatively irradiated locally advanced head and neck cancer patients.</Para>
              </AbstractSection>
            </Abstract>
            <Abstract ID="Abs2" Language="De" OutputMedium="All">
              <Heading>Zusammenfassung</Heading>
              <AbstractSection ID="ASec5">
                <Heading>Hintergrund</Heading>
                <Para>Entzündungsbasierte Bewertungssysteme haben eine potenzielle Bedeutung für die Beurteilung der Prognose von Krebspatienten. Derzeit fehlen jedoch ausreichend detailliert durchgeführte Analysen in Kollektiven von Patienten mit Kopf-Hals-Tumoren.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec6">
                <Heading>Methoden</Heading>
                <Para>Untersucht wurde das Gesamtüberleben („overall survival“, OS) von Patienten mit lokal fortgeschrittenen Kopf-Hals-Tumoren, die in kurativer Intention mit einer alleinigen primären Radiotherapie (RT), mit RT in Kombination mit Cetuximab (RIT) oder Cisplatin (RCHT) sowie mittels primärer Chirurgie gefolgt von postoperativer RT (PORT) behandelt wurden. Patienten, die primär radiotherapiert wurden (<Emphasis Type="Italic">N</Emphasis> = 170), wurden getrennt vom PORT-Kollektiv (<Emphasis Type="Italic">N</Emphasis> = 148) analysiert. OS wurde mittels der Kaplan-Meier-Methode ermittelt. Cox-proportionale Hazard-Regressionsmodelle wurden eingesetzt, um das Sterberisiko, stratifiziert nach Risikofaktoren und dem entzündungsbasierten Glasgow-Prognosescore (GPS), dem modifizierten GPS (mGPS), der Neutrophilen-Lymphozyten-Ratio (NLR), der Thrombozyten-Lymphozyten-Ratio (PLR) und dem Prognoseindex (PI) zu vergleichen.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec7">
                <Heading>Ergebnisse</Heading>
                <Para>Eine prognostische Bedeutung der untersuchten Bewertungssysteme wurde nur in der primär bestrahlten Patientengruppe, jedoch nicht im PORT-Kollektiv gefunden. Das Gesamtüberleben in GPS 0, 1 und 2 betrug jeweils 35,5, 18,8 und 15,4 Monate. Das Gesamtüberleben nach mGPS war in allen Gruppen identisch. Das PLR-Bewertungssystem hatte keine prognostische Relevanz, während das Gesamtüberleben in der NLR-0-Gruppe 27,3 und in der NLR-1-Gruppe 17,3 Monate betrug. Das Gesamtüberleben in PI 0 betrug 35,5, in PI 1 16,1 und in PI 2 22,6 Monate.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec8">
                <Heading>Schlussfolgerung</Heading>
                <Para>Die GPS/mGPS-Bewertungssysteme können bei primär, jedoch nicht bei postoperativ bestrahlten lokal fortgeschrittenen Kopf-Hals-Tumorpatienten zwischen 3 verschiedenen Risikogruppen diskriminieren.</Para>
              </AbstractSection>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>Prognosis</Keyword>
              <Keyword>Scoring system</Keyword>
              <Keyword>Glasgow Prognostic Score</Keyword>
              <Keyword>Overall survival</Keyword>
              <Keyword>Head and neck cancer</Keyword>
            </KeywordGroup>
            <KeywordGroup Language="De">
              <Heading>Schlüsselwörter</Heading>
              <Keyword>Prognose</Keyword>
              <Keyword>Klassifikationssystem</Keyword>
              <Keyword>Glasgow-Prognosescore</Keyword>
              <Keyword>Gesamtüberleben</Keyword>
              <Keyword>Kopf-Hals-Tumor</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>E.S. and A.G. should be regarded as equal contributors.</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <Body>
            <Para>A wealth of published data indicates that inflammation may be directly or indirectly associated with biological processes of cancer at the cellular and systemic levels and also affects the prognosis of cancer patients [<CitationRef CitationID="CR5">5</CitationRef>, <CitationRef CitationID="CR7">7</CitationRef>, <CitationRef CitationID="CR11">11</CitationRef>, <CitationRef CitationID="CR14">14</CitationRef>]. The impact of inflammation on cancer progression takes place via numerous mechanisms at the micro-environmental level, for example, through direct induction of tumor angiogenesis as well as through immune–modulatory effects. As has been pointed out by Hanahan and Weinberg [<CitationRef CitationID="CR6">6</CitationRef>, <CitationRef CitationID="CR13">13</CitationRef>] in the widely cited work on the evolution of cancer, the majority of solid tumors contain infiltrates of both the myeloid- and lymphoid-lineage cells [<CitationRef CitationID="CR30">30</CitationRef>]. These immune cells provide proliferative stimuli for neoplastic cells. Several types of cells of the immune system (e.g., macrophages, neutrophils, eosinophils, and other effectors) have been implicated in this process [<CitationRef CitationID="CR29">29</CitationRef>]. On the systemic level, the inflammatory response has been shown to be a common phenomenon in cancer patients [<CitationRef CitationID="CR23">23</CitationRef>, <CitationRef CitationID="CR24">24</CitationRef>] but biomarkers of inflammation have also been implicated in the prognosis of nonmalignant diseases [<CitationRef CitationID="CR3">3</CitationRef>, <CitationRef CitationID="CR4">4</CitationRef>].</Para>
            <Para>Recently published reviews about the prognostic value of inflammation markers in various types of cancer summarized the literature on data about the inflammation-based Glasgow Prognostic Score (GPS) [<CitationRef CitationID="CR17">17</CitationRef>, <CitationRef CitationID="CR18">18</CitationRef>, <CitationRef CitationID="CR24">24</CitationRef>]. Over 60 studies with more than 30,000 patients with various histological types of cancer (e.g., breast, ovarian, bladder, gynecological, prostate, gastric, esophageal, hematological, renal, colorectal, head and neck, hepatic, pancreatic, and lung cancer) are known. These data demonstrate the prognostic value of GPS, as well as of the so-called modified GPS (mGPS). GPS and mGPS are calculated by measuring the value of C-reactive protein (CRP) in combination with albumin concentrations, which allows a prognostic score that stratifies patients into three different risk groups to be calculated (see [<CitationRef CitationID="CR10">10</CitationRef>, <CitationRef CitationID="CR17">17</CitationRef>, <CitationRef CitationID="CR18">18</CitationRef>, <CitationRef CitationID="CR24">24</CitationRef>, <CitationRef CitationID="CR26">26</CitationRef>]). With respect to tumor type, the most robust evidence for a prognostic role of GPS/mGPS is available for primary resectable colorectal and renal cancers [<CitationRef CitationID="CR17">17</CitationRef>, <CitationRef CitationID="CR18">18</CitationRef>].</Para>
            <Para>Additional inflammation-based prognostic scores are known, among them the neutrophil–lymphocyte ratio (NLR), a combination of circulating neutrophil and lymphocyte counts, the platelet–lymphocyte ratio (PLR), a combination of platelet and lymphocyte counts, and the prognostic index (PI), a combination of C-reactive protein levels and white blood cell counts. For a comparative analysis of these prognostic scores see Proctor [<CitationRef CitationID="CR24">24</CitationRef>]. In head and neck cancer, the role of tumor environment and inflammation has been discussed in the literature [<CitationRef CitationID="CR8">8</CitationRef>]. Evidence for an association of inflammation with prognosis in head and neck cancer patients has been presented recently ([<CitationRef CitationID="CR1">1</CitationRef>, <CitationRef CitationID="CR2">2</CitationRef>, <CitationRef CitationID="CR9">9</CitationRef>, <CitationRef CitationID="CR15">15</CitationRef>, <CitationRef CitationID="CR16">16</CitationRef>, <CitationRef CitationID="CR19">19</CitationRef>, <CitationRef CitationID="CR22">22</CitationRef>] Grimm und Lazariotou [<CitationRef CitationID="CR12">12</CitationRef>], and references therein).</Para>
            <Para>The aim of this retrospective analysis was to analyze and compare the possible correlation of various inflammation marker-based prognostic scores with outcome (overall survival) in four well-characterized patient groups [primary radiotherapy, primary radiochemotherapy, primary radiotherapy in combination with cetuximab, and postoperative radiotherapy (PORT)], all of whom were treated at our institution [<CitationRef CitationID="CR20">20</CitationRef>, <CitationRef CitationID="CR21">21</CitationRef>].</Para>
            <Section1 ID="Sec1">
              <Heading>Material and methods</Heading>
              <Section2 ID="Sec2">
                <Heading>Patients</Heading>
                <Para>We included four distinctly treated patient groups as described above (RT, RCHT, RIT, and PORT). Only patients who were treated with curative intent without evidence of other malignancies were analyzed. A total of 361 patients, for whom outcome (overall survival) data were available, were evaluated. In 318 cases pretherapeutic albumin and CRP values were available for calculating the GPS score. Differential blood counts and other parameters of potential interest as inflammation markers were not wholly available for all patients. Patients included in this retrospective analysis were presented and discussed at the Institutional Tumor Board of the General Hospital Vienna. Patients treated at external institutions were not included in this retrospective analysis.</Para>
              </Section2>
              <Section2 ID="Sec3">
                <Heading>Surgery plus postoperative radiotherapy</Heading>
                <Para>Between 2002 and 2012, 167 patients were treated consecutively with surgery and adjuvant RT at the Department of Radiotherapy at the Medical University of Vienna (General Hospital Vienna). Of these, 148 patients with known preoperative albumin and CRP data were eligible for further analysis. Of the patients treated with postoperative RT, 9.4 % received combination chemotherapy.</Para>
              </Section2>
              <Section2 ID="Sec4">
                <Heading>Primary radiochemotherapy or radiotherapy alone</Heading>
                <Para>Patients treated from January 2001 to December 2006 with primary RCHT (<Emphasis Type="Italic">N</Emphasis> = 67) or with radiotherapy alone (<Emphasis Type="Italic">N</Emphasis> = 49) were included. Of these, 34 patients treated with primary RT (concomitant boost protocol) alone and 61 patients treated with RCHT were suitable (pretherapeutic CRP plus albumin values available) for analysis. The investigated patient group very closely resembles the patient collective described below that was treated with standard RT in combination with cetuximab with respect to age, tumor characteristics, and institutional selection criteria, particularly with regard to noneligibility for combination treatment with radiochemotherapy. During the above-mentioned period, chemotherapy was routinely combined with a concomitant boost technique (see below) at our institution. Concurrent chemotherapy consisted of daily low-dose cisplatin (6 mg/m<Superscript>2</Superscript>) during the first 20 days of treatment. A mitomycin C (MMC) bolus injection was given on day 21 of the treatment (day 1 of the fifth RT treatment week).</Para>
              </Section2>
              <Section2 ID="Sec5">
                <Heading>Radiotherapy plus cetuximab</Heading>
                <Para>Starting with the approval of cetuximab in 2006, 78 patients with HNSCC were treated consecutively with RIT at the Department of Radiotherapy at the Medical University of Vienna. Of these, 75 patients with documented pretherapeutic CRP and albumin levels were eligible for further analysis. Intravenous cetuximab was administered as previously described [<CitationRef CitationID="CR21">21</CitationRef>].</Para>
              </Section2>
              <Section2 ID="Sec6">
                <Heading>Radiotherapy</Heading>
                <Para>Standard fractionation RT, which was used in combination with cetuximab, was delivered up to a total dose of 70.0 Gy in 35 fractions (on work days; 2.0 Gy per fraction, over a 7-week period). The accelerated-fractionation RT (concomitant boost) protocol consists of 72.0 Gy given in 42 fractions over a 6-week period plus a concomitant boost comprising a twice-daily irradiation (1.8 and 1.5 Gy) for  the last 12 treatment days [<CitationRef CitationID="CR21">21</CitationRef>]. The total dose delivered with the concomitant boost protocol is 72.0 Gy to clinically manifest sites of gross disease and 54 Gy to adjacent lymphatic drainage regions at risk for subclinical metastasis. Before the introduction of cetuximab for the primary treatment in combination with radiotherapy, patients at our institution who were ineligible for chemotherapy were treated with the concomitant boost protocol. The RT group treated with cetuximab was treated by standard fractionation RT. This group displays similar clinical characteristics compared to the patients treated by the concomitant boost protocol before 2006 with regard to ineligibility for chemotherapy. All PORT patients received standard fractionation RT, which consisted of the delivery of 50–70 Gy at 2 Gy per fraction, depending on certain risk factors such as resection state and tumor stage [<CitationRef CitationID="CR28">28</CitationRef>]. In selected, high-risk patients [extra-capsular spread (ECS) and positive microscopic resection margins] chemotherapy (cisplatin) was added to radiotherapy. Spinal cord dose (independent of the fractionation protocol) was limited to 46 Gy, although in certain cases, higher doses up to 50 Gy were accepted.</Para>
              </Section2>
              <Section2 ID="Sec7">
                <Heading>Clinical evaluation and follow-up</Heading>
                <Para>The entire group of patients receiving RT was monitored weekly during RT. Clinical follow-up after the end of RT was conducted both at the Department of Radiotherapy and at the Department of Otorhinolaryngology (Head and Neck Surgery) according to our institutional guidelines.</Para>
              </Section2>
              <Section2 ID="Sec8">
                <Heading>Statistical analysis</Heading>
                <Para>Rates of overall survival (OS) were estimated by means of the Kaplan–Meier method and were compared between the groups using the log-rank test. Cox proportional-hazards models were used to estimate hazard ratios. Unadjusted and adjusted hazard ratios were utilized to obtain estimates of the differences in survival in relation to the investigated covariates. The software package SPSS Version 22 (IBM®) was used for statistical analysis.</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec9">
              <Heading>Results</Heading>
              <Para>Four differently treated patient groups (PORT, primary RCHT or RT alone, and RIT) were included in this retrospective analysis. No significant differences with respect to OS were found between the RCHT, RIT, and RT groups (with 3-year OS rates of 44, 27, and 22 %, respectively), while the OS estimate for the PORT treatment group (3-year OS rate 69 %) was significantly different from the non-PORT groups [<Emphasis Type="Italic">p</Emphasis> &lt; 0.001; log-rank test (Kaplan–Meier)]. Data from the conservatively treated patient groups (non-PORT group; <Emphasis Type="Italic">N</Emphasis> = 170) were pooled and analyzed separately from the PORT collective (<Emphasis Type="Italic">N</Emphasis> = 148). In Tables <InternalRef RefID="Tab1">1</InternalRef>, <InternalRef RefID="Tab2">2</InternalRef>, and <InternalRef RefID="Tab3">3</InternalRef>, the patients’ baseline characteristics are shown. Relative and absolute numbers of grading scores (PORT vs. non-PORT) are shown in Table <InternalRef RefID="Tab4">4</InternalRef>. Finally, OS analyses were performed according to different inflammation-based scoring systems (see Table <InternalRef RefID="Tab5">5</InternalRef>, modified from Proctor [<CitationRef CitationID="CR24">24</CitationRef>]). Kaplan–Meier curves of these analyses are presented in Fig. <InternalRef RefID="Fig1">1</InternalRef> and the corresponding OS estimates for the non-PORT group are presented in Table <InternalRef RefID="Tab6">6</InternalRef>. Median OS according to the Glasgow Prognostic Score (non-PORT) was 35.5 (GPS 0), 18.8 (GPS 1), and 15.4 (GPS 2) months, respectively. Differences between GPS 0 and GPS 1 were highly (<Emphasis Type="Italic">p</Emphasis> = 0.001) and between GPS 1 and 2 marginally (<Emphasis Type="Italic">p</Emphasis> = 0.06) significant [log-rank (Mantel–Cox) test]. Results based on the modified GPS were identical. The PLR scoring system was not useful for discriminating between different prognostic groups while NLR and PI scores had an impact on the prognosis in primarily irradiated patients (see Fig. <InternalRef RefID="Fig1">1</InternalRef> and Table <InternalRef RefID="Tab4">4</InternalRef> and <InternalRef RefID="Tab5">5</InternalRef>).<Figure Category="Standard" Float="Yes" ID="Fig1">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Overall survival estimates according to PORT and non-PORT treatment groups are shown. <Emphasis Type="Bold">a</Emphasis>, <Emphasis Type="Bold">f</Emphasis> Glasgow Prognostic Score (<Emphasis Type="Italic">GPS</Emphasis>); <Emphasis Type="Bold">b</Emphasis>, <Emphasis Type="Bold">g</Emphasis> modified GPS (<Emphasis Type="Italic">mGPS</Emphasis>); <Emphasis Type="Bold">c</Emphasis>, <Emphasis Type="Bold">h</Emphasis> neutrophil–lymphocyte ratio (<Emphasis Type="Italic">NLR</Emphasis>); <Emphasis Type="Bold">d</Emphasis>, <Emphasis Type="Bold">i</Emphasis> platelet–lymphocyte ratio (<Emphasis Type="Italic">PLR</Emphasis>); <Emphasis Type="Bold">e</Emphasis>, <Emphasis Type="Bold">j</Emphasis> prognostic index (<Emphasis Type="Italic">PI</Emphasis>)</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject ID="MO1">
                    <ImageObject Color="Color" FileRef="MediaObjects/66_2014_803_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                  </MediaObject>
                </Figure>
                <Table Float="Yes" ID="Tab1">
                  <Caption Language="En">
                    <CaptionNumber>Table 1</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Patients’ baseline characteristics</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="3">
                    <colspec align="left" colname="c1" colnum="1"/>
                    <colspec align="left" colname="c2" colnum="2"/>
                    <colspec align="left" colname="c3" colnum="3"/>
                    <thead>
                      <row>
                        <entry align="left" colname="c1" morerows="1">
                          <SimplePara>Characteristic</SimplePara>
                        </entry>
                        <entry align="left" nameend="c3" namest="c2">
                          <SimplePara>Treatment groups</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c2">
                          <SimplePara>PORT</SimplePara>
                          <SimplePara>(<Emphasis Type="Italic">N</Emphasis> = 148)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>Non-PORT</SimplePara>
                          <SimplePara>(<Emphasis Type="Italic">N</Emphasis> = 170)</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Age, years (median)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>58</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>61</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Male, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>115 (77.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>132 (77.6 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Female, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>33 (22.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>38 (22.4 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">Primary tumor site</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> Hypopharynx, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>25 (16.9 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>30 (17.7 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> Larynx, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>17 (11.5 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>23 (13.5 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> Oral cavity, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>36 (24.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>43 (25.3 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> Oropharynx, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>70 (47.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>74 (43.5 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">T stage, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>35 (23.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>1 (0.6 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>71 (48 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>24 (14.1 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>25 (16.9 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>39 (22.9 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 4</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>17 (11.5 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>106 (62.4 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">N stage, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>30 (20.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>21 (12.4 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>30 (20.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>11 (6.5 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>84 (56.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>131 (77 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>4 (2.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>7 (4.1 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">UICC stage, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> I</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>3 (2 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> II</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>18 (12.2 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>6 (3.5 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> III</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>29 (19.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>11 (6.5 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> IV</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>98 (66.2 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>153 (90 %)</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>
                      <Emphasis Type="Italic">PORT</Emphasis> primary surgery followed by postoperative radiotherapy, <Emphasis Type="Italic">UICC</Emphasis> Union Internationale Contre le Cancer</SimplePara>
                  </tfooter>
                </Table>
                <Table Float="Yes" ID="Tab2">
                  <Caption Language="En">
                    <CaptionNumber>Table 2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Non-PORT group of patients’ baseline characteristics</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="4">
                    <colspec align="left" colname="c1" colnum="1"/>
                    <colspec align="left" colname="c2" colnum="2"/>
                    <colspec align="left" colname="c3" colnum="3"/>
                    <colspec align="left" colname="c4" colnum="4"/>
                    <thead>
                      <row>
                        <entry align="left" colname="c1" morerows="1">
                          <SimplePara>Characteristic</SimplePara>
                        </entry>
                        <entry align="left" nameend="c4" namest="c2">
                          <SimplePara>Non-PORT treatment groups</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c2">
                          <SimplePara>RT (<Emphasis Type="Italic">N</Emphasis> = 34)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>RIT (<Emphasis Type="Italic">N</Emphasis> = 75)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>RCHT (<Emphasis Type="Italic">N</Emphasis> = 61)</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Age (median)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>61</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>65</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>55</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Male, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>26 (76.5 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>57 (76.0 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>49 (80.3 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Female, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>8 (23.5 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>18 (24.0 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>12 (19.7 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">Primary tumor site</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> Hypopharynx, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>8 (23.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>7 (9.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>15 (24.6 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> Larynx, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>7 (20.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>8 (10.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>8 (13.1 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> Oral cavity, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>4 (11.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>26 (34.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>13 (21.3 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> Oropharynx, no. (%)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>15 (44.1 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>34 (45.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>25 (51.0 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">T stage, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1 (3.4 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0 (0 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>9 (26.5 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>11 (14.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>3 (4.9 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>9 (26.5 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>14 (18.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>16 (26.2 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 4</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>15 (44.1 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>50 (66.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>42 (68.9 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">N stage, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>4 (11.8 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>14 (18.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>3 (4.9 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1 (3.4 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>8 (10.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>2 (3.3 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>28 (82.4 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>50 (66.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>53 (86.9 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1 (3.4 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>3 (4 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>3 (4.9 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">UICC stage, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> I</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0 (0 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0 (0 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0 (0 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> II</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>2 (5.9 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>4 (5.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0 (0 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> III</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>2 (5.9 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>8 (10.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>1 (1.6 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> IV</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>30 (88.2 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>63 (84 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>60 (98.4 %)</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>
                      <Emphasis Type="Italic">PORT</Emphasis> primary surgery followed by postoperative radiotherapy, <Emphasis Type="Italic">UICC</Emphasis> Union Internationale Contre le Cancer, <Emphasis Type="Italic">RT</Emphasis> radiotherapy alone, <Emphasis Type="Italic">RIT</Emphasis> radiotherapy in combination with cetuximab, <Emphasis Type="Italic">RCHT</Emphasis> radiotherapy in combination with cisplatin</SimplePara>
                  </tfooter>
                </Table>
                <Table Float="Yes" ID="Tab3">
                  <Caption Language="En">
                    <CaptionNumber>Table 3</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Values of inflammatory markers according to treatment groups</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="3">
                    <colspec align="left" colname="c1" colnum="1"/>
                    <colspec align="left" colname="c2" colnum="2"/>
                    <colspec align="left" colname="c3" colnum="3"/>
                    <thead>
                      <row>
                        <entry align="left" colname="c1" morerows="1">
                          <SimplePara>Inflammatory markers</SimplePara>
                        </entry>
                        <entry align="left" nameend="c3" namest="c2">
                          <SimplePara>Treatment groups</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c2">
                          <SimplePara>PORT (<Emphasis Type="Italic">N</Emphasis> = 148)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>Non-PORT (<Emphasis Type="Italic">N</Emphasis> = 170)</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Albumin</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>41.94</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>39.02</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>C-reactive protein</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>5</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>10</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Hemoglobin</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>14.10</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>13.18</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Thrombocytes</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>253</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>285</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Leukocytes</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>7.95</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>8.5</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Neutrophils</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>5.13</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>5.68</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Lymphocytes</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1.86</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>1.7</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Fibrinogen</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>413</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>469</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>Mean values are given except for CRP, for which median values are shown, because the variable is not normally distributed. <Emphasis Type="Italic">PORT</Emphasis> primary surgery followed by postoperative radiotherapy</SimplePara>
                  </tfooter>
                </Table>
                <Table Float="Yes" ID="Tab4">
                  <Caption Language="En">
                    <CaptionNumber>Table 4</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Distribution of scores according to treatment groups</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="3">
                    <colspec align="left" colname="c1" colnum="1"/>
                    <colspec align="left" colname="c2" colnum="2"/>
                    <colspec align="left" colname="c3" colnum="3"/>
                    <thead>
                      <row>
                        <entry align="left" colname="c1" morerows="1">
                          <SimplePara>Inflammation-based prognostic scores</SimplePara>
                        </entry>
                        <entry align="left" nameend="c3" namest="c2">
                          <SimplePara>Treatment groups</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c2">
                          <SimplePara>PORT (<Emphasis Type="Italic">N</Emphasis> = 148)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>Non-PORT (<Emphasis Type="Italic">N</Emphasis> = 170)</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">GPS, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>108 (73 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>81 (47.6 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>33 (22.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>63 (37.1 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>7 (4.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>26 (15.3 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">mGPS, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>112 (75.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>87 (51.2 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>29 (19.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>57 (33.5 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>7 (4.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>26 (15.3 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">NLR</Emphasis>
                            <Superscript>
                              <Emphasis Type="Bold">b</Emphasis>
                            </Superscript>
                            <Emphasis Type="Bold">, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>59 (49.2 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>53 (46.9 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>61 (50.8 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>60 (53.1 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">PLR, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>105 (71 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>103 (60.6 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>39 (26.3 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>53 (31.2 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>4 (2.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>14 (8.2 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c3" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">PI, no. (%)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>106 (71.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>83 (48.8 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>35 (23.6 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>68 (40 %)</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>7 (4.7 %)</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>19 (11.2 %)</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>Absolute numbers of patients differ between the scorings systems analyzed due to incomplete data for some of the blood values (platelets, leukocytes, neutrophils, lymphocytes).</SimplePara>
                    <SimplePara>
                      <Emphasis Type="Italic">PORT</Emphasis> primary surgery followed by postoperative radiotherapy, <Emphasis Type="Italic">GPS</Emphasis> Glasgow Prognostic Score, <Emphasis Type="Italic">mGPS</Emphasis> modified Glasgow Prognostic Score, <Emphasis Type="Italic">NLR</Emphasis> neutrophil–lymphocyte ratio, <Emphasis Type="Italic">PLR</Emphasis> platelet–lymphocyte ratio, <Emphasis Type="Italic">PI</Emphasis> prognostic index</SimplePara>
                  </tfooter>
                </Table>
                <Table Float="Yes" ID="Tab5">
                  <Caption Language="En">
                    <CaptionNumber>Table 5</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Inflammation-based scoring systems</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="2">
                    <colspec align="left" colname="c1" colnum="1"/>
                    <colspec align="left" colname="c2" colnum="2"/>
                    <thead>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Type of score</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>Score</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry align="left" nameend="c2" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">Glasgow Prognostic Score (GPS)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP &lt; 10 mg/l and albumin &gt; 35 g/l</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP &gt; 10 mg/l or albumin &lt; 35 g/l</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP &gt; 10 mg/l and albumin &lt; 35 g/l</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>2</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c2" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">Modified Glasgow Prognostic Score (mGPS)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP ≤ 10 mg/l and albumin ≥ 35 g/l</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP ≤ 10 mg/l and albumin &lt; 35 g/l</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP &gt; 10 mg/l</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP &gt; 10 mg/l and albumin &lt; 35 g/l</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>2</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c2" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">Neutrophil–lymphocyte ratio (NLR)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Neutrophil count:lymphocyte count &lt; 5:1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Neutrophil count:lymphocyte count ≥ 5:1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c2" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">Platelet–lymphocyte ratio (PLR)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Platelet count:lymphocyte count &lt; 150:1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Platelet count:lymphocyte count 150–300:1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Platelet count:lymphocyte count &gt; 300:1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>2</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c2" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">Prognostic index (PI)</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP ≤ 10 mg/l and leukocyte count ≤ 11 × 10<Superscript>9</Superscript>
                          </SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP ≤ 10 mg/l and leukocyte count &gt; 11 × 10<Superscript>9</Superscript>
                          </SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP &gt; 10 mg/l and leukocyte count ≤ 11 × 10<Superscript>9</Superscript>
                          </SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>CRP &gt; 10 mg/l and leukocyte count &gt; 11 × 10<Superscript>9</Superscript>
                          </SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>2</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>
                      <Emphasis Type="Italic">CRP</Emphasis> c-reactive protein</SimplePara>
                  </tfooter>
                </Table>
                <Table Float="Yes" ID="Tab6">
                  <Caption Language="En">
                    <CaptionNumber>Table 6</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Overall survival analyses of non-PORT treatment groups according to different inflammation-based scoring systems</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="4">
                    <colspec align="left" colname="c1" colnum="1"/>
                    <colspec align="left" colname="c2" colnum="2"/>
                    <colspec align="left" colname="c3" colnum="3"/>
                    <colspec align="left" colname="c4" colnum="4"/>
                    <thead>
                      <row>
                        <entry align="left" colname="c1"/>
                        <entry align="left" colname="c2">
                          <SimplePara>Median</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>Standard error</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>95 % CI</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">GPS</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>35.5</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>6.8</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>22.1–48.9</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>18.8</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>3.4</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>12.1–25.5</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>15.4</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>4.3</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>6.90–23.8</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Total</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>22.7</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>2.1</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>18.6–26.8</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">mGPS</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>33.5</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>6.6</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>20.5–46.4</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>18.8</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>3.4</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>12.1–25.5</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>15.4</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>4.3</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>6.90–23.8</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Total</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>22.7</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>2.1</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>18.6–26.8</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">NLR</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>27.3</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>4.4</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>18.8–36.2</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>17.3</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>3.7</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>14.2–28.6</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Total</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>23.7</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>2.9</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>18.1–29.3</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">PLR</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>23.0</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>2.6</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>18.0–28.1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>23.7</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>4.6</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>14.7–32.6</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>14.1</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>5.4</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>24.7–24.7</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Total</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>22.7</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>2.1</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>26.8–26.8</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">PI</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>0</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>35.5</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>7.0</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>21.8–49.1</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>16.1</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>1.6</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>13.0–19.2</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>22.6</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>7.6</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>7.70–37.4</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Total</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>22.7</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>2.1</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>18.6–26.8</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>
                      <Emphasis Type="Italic">GPS</Emphasis> Glasgow Prognostic Score, <Emphasis Type="Italic">mGPS</Emphasis> modified Glasgow Prognostic Score, <Emphasis Type="Italic">NLR</Emphasis> neutrophil–lymphocyte ratio, <Emphasis Type="Italic">PLR</Emphasis> platelet–lymphocyte ratio, <Emphasis Type="Italic">PI</Emphasis> prognostic index, <Emphasis Type="Italic">CI</Emphasis> confidence interval</SimplePara>
                  </tfooter>
                </Table>
              </Para>
              <Para>Next we assessed the impact of various clinical factors and prognostic scores on survival in univariate as well as multivariate analyses for the non-PORT collective (see Tables <InternalRef RefID="Tab7">7</InternalRef> and <InternalRef RefID="Tab8">8</InternalRef>). Of note, the primarily irradiated collective was very homogeneous with regard to tumor staging as 90 % of the patients had UICC stage IV disease, while only 6 patients had stage II and 11 patients stage III disease. Due to the small number of patients in the less advanced stages II or III, potential statistical differences of the impact of distinct UICC stages on survival could not be calculated. In univariate analysis, tumor size [T1–3 combined versus T4 alone: HR = 0.62; <Emphasis Type="Italic">p</Emphasis> = 0.01; 95 % confidence interval (CI) = 0.43–0.90] had a significant impact on prognosis, while lymph-node status (N0–2a versus N2b–3: HR = 0.66; <Emphasis Type="Italic">p</Emphasis> = 0.08; 95 % CI = 0.41–1.05) was marginally significant. T and N stage were grouped into T1–3 versus T4 and N0–2a versus N2b–3, in order to facilitate comparison of our data with the classification of risk-of-death groups as described [<CitationRef CitationID="CR2">2</CitationRef>, <CitationRef CitationID="CR21">21</CitationRef>]. As might be expected from the OS estimates presented above, the GPS and mGPS scoring systems had comparable and significant impact on prognosis. Results of the univariate analyses of PI, NLR, and PLR scores were also compatible with the OS data. Multivariate Cox regression analysis of the impact on OS was performed, omitting the non-PORT group, by including various factors (GPS, mGPS, PI, NLR, PLR, T stage, N stage), the results of which are presented in Table <InternalRef RefID="Tab8">8</InternalRef>. In this analysis, GPS 0/1, mGPS 1–3, NLR, PI 1/2, but not PLR remained significant determinants of OS. GPS 2 was marginally significant.<Table Float="Yes" ID="Tab7">
                  <Caption Language="En">
                    <CaptionNumber>Table 7</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Non-PORT univariate analysis</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="4">
                    <colspec align="left" colname="c1" colnum="1"/>
                    <colspec align="left" colname="c2" colnum="2"/>
                    <colspec align="left" colname="c3" colnum="3"/>
                    <colspec align="left" colname="c4" colnum="4"/>
                    <thead>
                      <row>
                        <entry align="left" colname="c1"/>
                        <entry align="left" colname="c2">
                          <SimplePara>Hazard ratio</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>95 % CI</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>
                            <Emphasis Type="Italic">p</Emphasis>-value</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Age (median)</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1.03</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.73–1.46</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.90</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>Sex</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1.00</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.67–1.52</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.98</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>T1–3 vs. T4</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.62</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.43–0.90</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.01</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>N0–2a vs. N2b–3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.66</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.41–1.02</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.08</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">GPS</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.32</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.19–0.52</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>&lt; 0.00</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 1 vs. 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.61</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.38–0.99</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.05</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">mGPS</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 0 vs.1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.34</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.21–0.55</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>&lt; 0.00</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 1 vs. 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.60</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.37–0.98</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.04</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">NLR</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1"/>
                        <entry align="left" colname="c2">
                          <SimplePara>0.56</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.35–0.89</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.02</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">PLR</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.55</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.29–1.05</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.07</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 1 vs. 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.60</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.31–1.20</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.15</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">PI</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.46</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.27–0.78</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>&lt; 0.00</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara> 1 vs. 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.99</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.58–1.69</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.97</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>
                      <Emphasis Type="Italic">GPS</Emphasis> Glasgow Prognostic Score, <Emphasis Type="Italic">mGPS</Emphasis> modified Glasgow Prognostic Score, <Emphasis Type="Italic">NLR</Emphasis> neutrophil–lymphocyte ratio, <Emphasis Type="Italic">PLR</Emphasis> platelet–lymphocyte ratio, <Emphasis Type="Italic">PI</Emphasis> prognostic index, <Emphasis Type="Italic">CI</Emphasis> confidence interval</SimplePara>
                  </tfooter>
                </Table>
                <Table Float="Yes" ID="Tab8">
                  <Caption Language="En">
                    <CaptionNumber>Table 8</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Non-PORT multivariate analysis according to different scoring systems in conjunction with clinical staging parameters</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="4">
                    <colspec align="left" colname="c1" colnum="1"/>
                    <colspec align="left" colname="c2" colnum="2"/>
                    <colspec align="left" colname="c3" colnum="3"/>
                    <colspec align="left" colname="c4" colnum="4"/>
                    <thead>
                      <row>
                        <entry align="left" colname="c1"/>
                        <entry align="left" colname="c2">
                          <SimplePara>Hazard ratio</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>95 % CI</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>
                            <Emphasis Type="Italic">p</Emphasis>-value</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">GPS</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>GPS 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.35</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.21–0.58</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.00</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>GPS 1 vs. 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.63</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.39–1.03</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.07</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>T1–3 vs. T4</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.75</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.51–1.10</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.13</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>N0–2a vs. N2b–3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.77</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.48–1.24</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.29</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">mGPS</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>mGPS 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.38</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.23–0.62</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.00</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>mGPS 1 vs. 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.06</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.38–1.03</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.06</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>T1–3 vs. T4</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.73</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.50–1.10</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.12</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>N0–2a vs. N2b–3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.75</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.47–1.21</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.24</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">NLR</Emphasis>
                          </SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.78</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.50–1.21</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.27</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>NLR 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.54</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.33–0.87</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.12</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>T1–3 vs. T4</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.81</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.50–1.29</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.37</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>N0–2a vs. N2b–3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.80</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.44–0.80</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.50</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">PLR</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>PLR 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.56</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.30–1.07</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.08</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>PLR 1 vs. 2</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.57</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.29–1.12</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.10</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>T1–3 vs. T4</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.65</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.45–0.94</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.02</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>N0–2a vs. N2b–3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.68</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.42–1.10</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.11</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" nameend="c4" namest="c1">
                          <SimplePara>
                            <Emphasis Type="Bold">PI</Emphasis>
                          </SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>PI 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.49</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.28–0.86</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.01</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>PI 0 vs. 1</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>1.00</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.59–1.72</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.99</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>T1–3 vs. T4</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.76</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.52–1.11</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.16</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry align="left" colname="c1">
                          <SimplePara>N0–2a vs. N2b–3</SimplePara>
                        </entry>
                        <entry align="left" colname="c2">
                          <SimplePara>0.68</SimplePara>
                        </entry>
                        <entry align="left" colname="c3">
                          <SimplePara>0.43–1.10</SimplePara>
                        </entry>
                        <entry align="left" colname="c4">
                          <SimplePara>0.11</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>
                      <Emphasis Type="Italic">GPS</Emphasis> Glasgow Prognostic Score, <Emphasis Type="Italic">mGPS</Emphasis> modified Glasgow Prognostic Score, <Emphasis Type="Italic">NLR</Emphasis> neutrophil–lymphocyte ratio, <Emphasis Type="Italic">PLR</Emphasis> platelet–lymphocyte ratio, <Emphasis Type="Italic">PI</Emphasis> prognostic index, <Emphasis Type="Italic">CI</Emphasis> confidence interval</SimplePara>
                  </tfooter>
                </Table>
              </Para>
            </Section1>
            <Section1 ID="Sec10">
              <Heading>Discussion</Heading>
              <Para>Here we show that markers of the systemic inflammatory response may have an important role in the assessment of patients with head and neck cancer who were treated either surgically in combination with PORT or with primary RT alone as well as in combination with systemic therapy. Comparative analysis between the PORT and non-PORT group revealed a large difference in OS rates between these two groups. The 3-year OS rates were 44 % for the RCHT, 27 % for RIT, and 22 % for the RT-alone group, while the OS estimate for the PORT group at 3 years was 69 %. The difference in survival outcome between the PORT and the non-PORT group was significant (<Emphasis Type="Italic">p</Emphasis> &lt; 0.001; log-rank test). No significant difference with respect to OS was found between the RCHT, RIT, and RT groups. The potential impact of different scoring systems was therefore analyzed separately for the PORT and non-PORT group. However, no correlation between the inflammatory scoring systems used and OS in the PORT group could be detected.</Para>
              <Para>Further analyses were therefore limited to the non-PORT group. The results of Kaplan–Meier estimates in the non-PORT group indicate that the scoring systems tested may be able to discriminate between prognostically favorable and unfavorable patients treated with primary radiotherapy. GPS and mGPS were almost identical regarding their prognostic relevance, as only for one patient a different score value was calculated. Median OS times according to GPS 0, 1, and 2 were 1099 days, 583 days, and 476 days, respectively. By comparison, median OS times according to mGPS 0, 1, and 2 were 1037 days, 583 days, and 476 days, respectively. The PLR scoring system was not of prognostic relevance in our data set. The survival difference between NLR 0 and NLR 1 was significant (<Emphasis Type="Italic">p</Emphasis> = 0.15; log-rank test). Median OS in the NLR group was 847 days and in the NLR 1 group 537 days. The PI scoring system yielded statistically relevant differences between PI 0 and PI 1 as well as between PI 0 and PI 2 (each <Emphasis Type="Italic">p</Emphasis> ≤ 0.001 according to the log-rank test). Differences between PI 1 and PI 2 were not significant. Median OS was 1099 days in PI 0, 500 days in PI 1, and 700 days in PI 2. The primarily irradiated patient (non-PORT) collective was very homogenous regarding risk factors, as it consisted of predominantly locally advanced cancers (90 % stage IV cancer; 66 % T4 tumors; 79 % N2b–N3 lymph-node stage), thus, simplifying interpretation of the impact of the scoring system on OS, which was confirmed by univariate analysis (Table <InternalRef RefID="Tab7">7</InternalRef>). Multivariate Cox regression analyses of the impact on OS including various factors (GPS, mGPS, PI, NLR, PLR, T stage, N stage), the results of which are presented in Table <InternalRef RefID="Tab8">8</InternalRef>, were performed. In this analysis, GPS 0/1, mGPS 1–3, NLR, PI 1/2, but not PLR remained significant determinants of OS. GPS 2 versus GP 1 was marginally significant.</Para>
              <Para>As mentioned in the introduction, in head and neck cancer, relatively few publications covering different and in part heterogeneous head and neck cancer patient collectives are available. Grimm und Lazariotou [<CitationRef CitationID="CR12">12</CitationRef>] retrospectively analyzed oral squamous cell carcinoma (OSCC) patients who were treated with primary resection alone (52.9 %) or by resection followed by RT with/without chemotherapy (6.4 and 25.7 %, respectively) or followed by brachytherapy (15 %). Of their collective, 33.7 % were UICC stage IV patients, compared to 66.2 % in our PORT group, of which 9.4 % received PORT in combination with chemotherapy. Because the surgery plus RT group was not analyzed separately by Grimm et al., a direct comparison with our data is not reasonable. In addition, Grimm et al. used a different prognostic index, labeled LPI (laboratory prognostic index), which was calculated from elevated CRP and white blood count as well as low hemoglobin values and that was used to categorize patients into four different groups. Multivariate analysis demonstrated that a high LPI was an independent prognostic factor for survival. Fang et al. [<CitationRef CitationID="CR9">9</CitationRef>] analyzed preoperative NLR and CRP levels in OSCC patients treated by surgery followed by RT with/without chemotherapy. However, no detailed description of the percentage of patients treated by either surgery alone or by RT and/or RTCHT was presented in this publication. The authors concluded that a high NLR is associated with a significantly worsened OS compared to the low NLR OSCC group. Persianidis et al. [<CitationRef CitationID="CR22">22</CitationRef>] recently showed that a high pretreatment NLR (in a multivariate analysis) is associated with a poor disease-specific survival in patients with advanced OSCC (91 % UICC stage IV) treated with preoperative radiochemotherapy. Khandavilli et al. [<CitationRef CitationID="CR16">16</CitationRef>] investigated pretreatment CRP as a prognostic indicator in OSCC patients treated by primary resection followed by RT. However, data on the proportion of patients who were irradiated after surgery were not presented. They found in a multivariate analysis that elevated CRP values were associated with a reduced OS.</Para>
              <Para>In summary, we were able to confirm the conclusion by Procter et al. ([<CitationRef CitationID="CR24">24</CitationRef>], and references therein) that mGPS (as well as GPS) are well suited for determining prognosis in patients. The nearly perfect overlap with regard to prognostic significance between the modified GPS and GPS system also supports the statement that hypo-albuminemia without an elevated CRP level is rare [<CitationRef CitationID="CR18">18</CitationRef>]. The finding that all scoring systems investigated (mGPS, GPS, PLR, as well as PI and NLR) did not predict prognosis in the PORT group was unexpected and we are not able to provide a rationale for this observation. However, to the best of our knowledge, the relevance of prognostic scoring systems in sufficiently well-defined postoperatively irradiated treatment groups has not been investigated so far. Compared to recent publications cited above, which included only OSCC patients, our study population in the PORT group consisted of only 24.3 % OSCC patients. In addition, all patients in our operated collective were treated by postoperative RT, which was not the case in the above mentioned publications.</Para>
            </Section1>
            <Section1 ID="Sec11" Type="Conclusion">
              <Heading>Conclusion</Heading>
              <Para>Several authors [<CitationRef CitationID="CR2">2</CitationRef>, <CitationRef CitationID="CR25">25</CitationRef>, <CitationRef CitationID="CR27">27</CitationRef>, <CitationRef CitationID="CR28">28</CitationRef>] have discussed the role of incorporating tumor stage, HPV/p16 status, and smoking habits in oropharyngeal cancer patients in order to subdivide patients into different risk groups. Inflammatory scoring systems may have the potential to play a similar important role if analyzed consequently in well-characterized treatment groups. As our retrospective analysis represents a single institution treatment collective, validation of our observations by other groups and in prospective studies would be helpful. Such studies may provide additional tools to predict outcome and opportunities for trial stratification.</Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/66_2014_Article_803.pdf" OutputMedium="All" PDFType="Typeset" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Ethics>
              <Heading>Compliance with ethical guidelines</Heading>
              <FormalPara RenderingStyle="Style1">
                <Heading>Conflict of Interest</Heading>
                <Para>E. Selzer, A. Grah, G. Heiduschka, G, Kornek, and D. Thurnher state that there are no conflicts of interest.</Para>
                <Para>The accompanying manuscript does not include studies on humans or animals.</Para>
              </FormalPara>
            </Ethics>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>An</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PR</Initials>
                    <FamilyName>Ding</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FH</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WQ</Initials>
                    <FamilyName>Jiang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>YH</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma</ArticleTitle>
                  <JournalTitle>Tumour Biol</JournalTitle>
                  <VolumeID>32</VolumeID>
                  <FirstPage>317</FirstPage>
                  <LastPage>324</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s13277-010-0124-7</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXitleitrk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21052888</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>An X, Ding PR, Wang FH, Jiang WQ, Li YH (2011) Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol 32:317–324</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KK</Initials>
                    <FamilyName>Ang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Harris</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Wheeler</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Human papillomavirus and survival of patients with oropharyngeal cancer</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>363</VolumeID>
                  <FirstPage>24</FirstPage>
                  <LastPage>35</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJMoa0912217</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2943767</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXpslyjtr8%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20530316</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Azab</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Shah</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Radbel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Tan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Bhatt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Vonfrolio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Habeshy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Picon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Bloom</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients</ArticleTitle>
                  <JournalTitle>Med Oncol</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>432</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s12032-012-0432-4</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23283648</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, Habeshy A, Picon A, Bloom S (2013) Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol 30:432</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Azab</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Shariff</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Bachir</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JP</Initials>
                    <FamilyName>Nabagiez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>McGinn</FamilyName>
                    <Suffix>Jr</Suffix>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Elevated preoperative neutrophil/lymphocyte ratio as a predictor of increased long-term survival in minimal invasive coronary artery bypass surgery compared to sternotomy</ArticleTitle>
                  <JournalTitle>J Cardiothorac Surg</JournalTitle>
                  <VolumeID>8</VolumeID>
                  <FirstPage>193</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1749-8090-8-193</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3850883</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24070055</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Azab B, Shariff MA, Bachir R, Nabagiez JP, McGinn JT Jr (2013) Elevated preoperative neutrophil/lymphocyte ratio as a predictor of increased long-term survival in minimal invasive coronary artery bypass surgery compared to sternotomy. J Cardiothorac Surg 8:193</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Balkwill</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Mantovani</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Inflammation and cancer: back to Virchow?</ArticleTitle>
                  <JournalTitle>Lancet</JournalTitle>
                  <VolumeID>357</VolumeID>
                  <FirstPage>539</FirstPage>
                  <LastPage>545</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0140-6736(00)04046-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXhsVKltb0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11229684</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539–545</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Colotta</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Allavena</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Sica</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability</ArticleTitle>
                  <JournalTitle>Carcinogenesis</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>1073</FirstPage>
                  <LastPage>1081</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/carcin/bgp127</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Colotta F, Allavena P, Sica A et al (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 7:1073–1081</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LM</Initials>
                    <FamilyName>Coussens</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Werb</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Inflammation and cancer</ArticleTitle>
                  <JournalTitle>Nature</JournalTitle>
                  <VolumeID>420</VolumeID>
                  <FirstPage>860</FirstPage>
                  <LastPage>867</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/nature01322</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2803035</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XpsFygtb4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12490959</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Curry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Sprandio</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Cognetti</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Luginbuhl</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Bar-Ad</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Pribitkin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Tuluc</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Tumor microenvironment in head and neck squamous cell carcinoma</ArticleTitle>
                  <JournalTitle>Semin Oncol</JournalTitle>
                  <VolumeID>41</VolumeID>
                  <FirstPage>217</FirstPage>
                  <LastPage>234</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1053/j.seminoncol.2014.03.003</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2cXns1Clur8%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24787294</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Curry JM, Sprandio J, Cognetti D, Luginbuhl A, Bar-Ad V, Pribitkin E, Tuluc M (2014) Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol 41:217–234</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HY</Initials>
                    <FamilyName>Fang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>XY</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HT</Initials>
                    <FamilyName>Chien</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Chang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CT</Initials>
                    <FamilyName>Liao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JJ</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FC</Initials>
                    <FamilyName>Wei</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HM</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>IH</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CJ</Initials>
                    <FamilyName>Kang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SF</Initials>
                    <FamilyName>Huang</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma</ArticleTitle>
                  <JournalTitle>Laryngoscope</JournalTitle>
                  <VolumeID>123</VolumeID>
                  <FirstPage>2690</FirstPage>
                  <LastPage>2699</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/lary.24105</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3sXhslWnsbbL</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23619955</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Fang HY, Huang XY, Chien HT, Chang JT, Liao CT, Huang JJ, Wei FC, Wang HM, Chen IH, Kang CJ, Huang SF (2013) Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma. Laryngoscope 123:2690–2699</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LM</Initials>
                    <FamilyName>Forrest</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>McMillan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CS</Initials>
                    <FamilyName>McArdle</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WJ</Initials>
                    <FamilyName>Angerson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DJ</Initials>
                    <FamilyName>Dunlop</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer</ArticleTitle>
                  <JournalTitle>Br J Cancer</JournalTitle>
                  <VolumeID>89</VolumeID>
                  <FirstPage>1028</FirstPage>
                  <LastPage>1030</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.bjc.6601242</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2376960</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3svisVOjsg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12966420</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small cell lung cancer. Br J Cancer 89:1028–1030</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Gabay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Kuschner</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Acute-phase proteins and other systemic responses to inflammation</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>340</VolumeID>
                  <FirstPage>1376</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM199904293401723</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gabay C, Kuschner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340:1376</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12</CitationNumber>
                <BibUnstructured>Grimm M, Lazariotou M (2012) Clinical relevance of a new pre-treatment laboratory prognostic index in patients with oral squamous cell carcinoma. Med Oncol 29:1435–47</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Hanahan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Weinberg</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Hallmarks of cancer: the next generation</ArticleTitle>
                  <JournalTitle>Cell</JournalTitle>
                  <VolumeID>144</VolumeID>
                  <FirstPage>646</FirstPage>
                  <LastPage>674</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.cell.2011.02.013</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXjsFeqtrk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21376230</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674 (Review)</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Hanahan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LM</Initials>
                    <FamilyName>Coussens</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Accessories to the crime: functions of cells recruited to the tumor microenvironment</ArticleTitle>
                  <JournalTitle>Cancer Cell</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>309</FirstPage>
                  <LastPage>322</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ccr.2012.02.022</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38Xkt1ykt7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22439926</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Hanahan D, Coussens LM (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:309–322 (Review)</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>He</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GP</Initials>
                    <FamilyName>Shen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ZF</Initials>
                    <FamilyName>Ren</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Qin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Cui</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma</ArticleTitle>
                  <JournalTitle>Head Neck</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>1769</FirstPage>
                  <LastPage>1776</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/hed.22008</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22318781</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>He JR, Shen GP, Ren ZF, Qin H, Cui C, Zhang Y et al (2012) Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck 34:1769–1776</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SD</Initials>
                    <FamilyName>Khandavilli</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PO</Initials>
                    <FamilyName>Ceallaigh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CJ</Initials>
                    <FamilyName>Lloyd</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Whitaker</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma</ArticleTitle>
                  <JournalTitle>Oral Oncol</JournalTitle>
                  <VolumeID>45</VolumeID>
                  <FirstPage>912</FirstPage>
                  <LastPage>914</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.oraloncology.2009.03.015</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXhtFGnsb7P</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19502100</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R (2009) Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol 45:912–914</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>McMillan</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">An inflammation-based prognostic score and its role in the nutrition based management of patients with cancer</ArticleTitle>
                  <JournalTitle>Proc Nutr Soc</JournalTitle>
                  <VolumeID>67</VolumeID>
                  <FirstPage>257</FirstPage>
                  <LastPage>262</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1017/S0029665108007131</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18452641</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>McMillan DC (2008) An inflammation-based prognostic score and its role in the nutrition based management of patients with cancer. Proc Nutr Soc 67:257–262</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>McMillan</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer</ArticleTitle>
                  <JournalTitle>Cancer Treat Rev</JournalTitle>
                  <VolumeID>39</VolumeID>
                  <FirstPage>534</FirstPage>
                  <LastPage>540</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ctrv.2012.08.003</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22995477</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 39:534–540 (Review)</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CR</Initials>
                    <FamilyName>Millrud</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Månsson Kvarnhammar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Uddman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Björnsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Riesbeck</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LO</Initials>
                    <FamilyName>Cardell</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival</ArticleTitle>
                  <JournalTitle>PLoS One</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>e51120</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1371/journal.pone.0051120</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3519486</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhvFSks7zM</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23251433</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Millrud CR, Månsson Kvarnhammar A, Uddman R, Björnsson S, Riesbeck K, Cardell LO (2012) The activation pattern of blood leukocytes in head and neck squamous cell carcinoma is correlated to survival. PLoS One 7:e51120</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20</CitationNumber>
                <BibUnstructured>Heiduschka G, Grah A, Oberndorfer F, Kadletz L, Altorjai G, Kornek G, Wrba F, Thurnher D, Selzer E (2014). Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy. Strahlenther Onkol. 2014 Sep 25. [Epub ahead of print].</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21</CitationNumber>
                <BibUnstructured>Heiduschka G, Grah A, Oberndorfer F, Seemann R, Kranz A, Kornek G, Wrba F, Thurnher D, Selzer E (2014). Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab. Strahlenther Onkol 190:832–8.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Perisanidis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Kornek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PW</Initials>
                    <FamilyName>Pöschl</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Holzinger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Pirklbauer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Schopper</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Ewers</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer</ArticleTitle>
                  <JournalTitle>Med Oncol</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>334</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s12032-012-0334-5</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23292862</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Perisanidis C, Kornek G, Pöschl PW, Holzinger D, Pirklbauer K, Schopper C, Ewers R (2013) High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer. Med Oncol 30:334</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Proctor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Talwar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Balmar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>O’Reilly</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Foulis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PG</Initials>
                    <FamilyName>Horgan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>Morrison</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>McMillan</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study</ArticleTitle>
                  <JournalTitle>Br J Cancer</JournalTitle>
                  <VolumeID>103</VolumeID>
                  <FirstPage>870</FirstPage>
                  <LastPage>876</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.bjc.6605855</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2966631</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXhtFaitL7I</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20717110</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Proctor MJ, Talwar D, Balmar SM, O’Reilly DS, Foulis AK, Horgan PG, Morrison DS, McMillan DC (2010) The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 103:870–876</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>Proctor</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>Morrison</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Talwar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Balmer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CD</Initials>
                    <FamilyName>Fletcher</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>O’Reilly</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Foulis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>PG</Initials>
                    <FamilyName>Horgan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>McMillan</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study</ArticleTitle>
                  <JournalTitle>Eur J Cancer</JournalTitle>
                  <VolumeID>47</VolumeID>
                  <FirstPage>2633</FirstPage>
                  <LastPage>2641</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.ejca.2011.03.028</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21724383</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47:2633–2641</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Rades</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ND</Initials>
                    <FamilyName>Seibold</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MP</Initials>
                    <FamilyName>Gebhard</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Noack</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SE</Initials>
                    <FamilyName>Schild</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Thorns</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN)</ArticleTitle>
                  <JournalTitle>Strahlenther Onkol</JournalTitle>
                  <VolumeID>187</VolumeID>
                  <FirstPage>626</FirstPage>
                  <LastPage>632</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00066-011-1139-8</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rades D, Seibold ND, Gebhard MP, Noack F, Schild SE, Thorns C (2013) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626–632</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CS</Initials>
                    <FamilyName>Roxburgh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>McMillan</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Role of systemic inflammatory response in predicting survival in patients with primary operable cancer</ArticleTitle>
                  <JournalTitle>Future Oncol</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>149</FirstPage>
                  <LastPage>163</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.2217/fon.09.136</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXhsFyitL3P</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20021215</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6:149–163 (Review)</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Rutkowski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Wygoda</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Składowski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Hejduk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Rutkowski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Kołosza</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Maciejewski</FamilyName>
                  </BibAuthorName>
                  <Year>2013</Year>
                  <ArticleTitle Language="En">Prognostic role of tumor volume for radiotherapy outcome in patient with T2 laryngeal cancer</ArticleTitle>
                  <JournalTitle>Strahlenther Onkol</JournalTitle>
                  <VolumeID>189</VolumeID>
                  <FirstPage>861</FirstPage>
                  <LastPage>866</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00066-013-0411-5</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BC3sbivVaksQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23982169</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rutkowski T, Wygoda A, Składowski K, Hejduk B, Rutkowski R, Kołosza Z, Maciejewski B (2013) Prognostic role of tumor volume for radiotherapy outcome in patient with T2 laryngeal cancer. Strahlenther Onkol 189:861–866</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Sadat</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Wienke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Dunst</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Kuhnt</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Survival of patients with head and neck cancer. Impact of physical status and comorbidities</ArticleTitle>
                  <JournalTitle>Strahlenther Onkol</JournalTitle>
                  <VolumeID>188</VolumeID>
                  <FirstPage>62</FirstPage>
                  <LastPage>70</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s00066-011-0009-8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BC383islKhtg%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>22189439</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sadat F, Wienke A, Dunst J, Kuhnt T (2012) Survival of patients with head and neck cancer. Impact of physical status and comorbidities. Strahlenther Onkol 188:62–70</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Stockmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Schadendorf</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Klose</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Helfrich</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">The impact of the immune system on tumor: angiogenesis and vascular remodeling</ArticleTitle>
                  <JournalTitle>Front Oncol</JournalTitle>
                  <VolumeID>4</VolumeID>
                  <FirstPage>69</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.3389/fonc.2014.00069</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3986554</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24782982</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Stockmann C, Schadendorf D, Klose R, Helfrich I (2014) The impact of the immune system on tumor: angiogenesis and vascular remodeling. Front Oncol 4:69 (Review)</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>TD</Initials>
                    <FamilyName>Tlsty</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LM</Initials>
                    <FamilyName>Coussens</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Tumor stroma and regulation of cancer development</ArticleTitle>
                  <JournalTitle>Annu Rev Pathol</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>119</FirstPage>
                  <LastPage>150</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1146/annurev.pathol.1.110304.100224</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XktVOitb0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18039110</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of cancer development. Annu Rev Pathol 1:119–150</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
